LOGIN  |  REGISTER
Chimerix
Compass Therapeutics

Pro-Dex Announces Fiscal 2024 Fourth Quarter and Full-Year Results

September 05, 2024 | Last Trade: US$48.74 2.39 5.16

IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.

Quarter Ended June 30, 2024

Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $2.0 million in sales of new units to that same customer. Gross profit for the three months ended June 30, 2024 increased $729,000, or 22%. Although gross profit increased, our gross margin decreased from 32% for the three months ended June 30, 2023, to 27% for the three months ended June 30, 2024, due to continued price pressures and increased indirect labor in our operations group to manage our growth.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended June 30, 2024, remained relatively flat at $1.7 million, compared to $1.8 million for the prior fiscal year's corresponding quarter. While these total operating expense amounts have remained flat, we reduced general and administrative expenses by $182,000 and increased engineering expenses by $141,000 for the quarter ended June 30, 2024, compared to the corresponding quarter in 2023. The decrease in general and administrative expenses is a result of reduced equity compensation expenses due to employee forfeitures and the increase in engineering relates to a higher proportion of sustaining engineering expenses as opposed to billable customer contract expenses.

Our operating income for the quarter ended June 30, 2024, increased $742,000, or 46%, to $2.4 million compared to $1.6 million for the prior fiscal year's corresponding quarter. The increase reflects our increased sales and gross profit, as described above.

Net income for the quarter ended June 30, 2024, increased slightly by $86,000 to $1.6 million, or $0.46 per diluted share, compared to $1.5 million, or $0.42 per diluted share, in the corresponding quarter in 2023. The difference in the growth rate of net income and operating income is primarily due to unrealized gains and losses of investments. In the current quarter, operating income increased 46% over the corresponding quarter of the prior fiscal year compared to the slight increase in net income for the same period.

Year Ended June 30, 2024

Net sales for the fiscal year ended June 30, 2024 increased $7.8 million, or 17%, to $53.8 million from $46.0 million for the fiscal year ended June 30, 2023, due primarily to increases in revenue from our largest customer. Specifically, the increase relates to a $3.6 million increase in repair revenue as well as an increase of $3.5 million in sales of new units to that same customer.

Gross profit for the fiscal year ended June 30, 2024, increased $1.8 million, or 14%, to $14.5 million compared to $12.7 million for fiscal 2023.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the fiscal year ended June 30, 2024, increased 6% to $7.4 million from $7.0 million in the prior fiscal year. The increase relates primarily to an increase in research and development costs because in fiscal 2024 our expenditures related primarily to sustaining engineering activities rather than billable customer projects which are reclassified to cost of sales.

Our operating income for the year ended June 30, 2024, increased $1.4 million, or 25%, to $7.2 million compared to $5.8 million for the prior fiscal year's corresponding quarter. The increase reflects our increased sales and gross profit, as described above.

Net income for the fiscal year ended June 30, 2024, was $2.1 million, or $0.60 per diluted share, compared to $7.1 million, or $1.95 per diluted share, for fiscal 2023. Our net income for the year ended June 30, 2024, contains unrealized losses on our marketable equity investments of $4.1 million while our net income for the year ended June 30, 2023, contains unrealized gains on our marketable equity investments of $3.9 million. The difference in the growth rate of net income and operating income is primarily due to unrealized gains and losses of investments. In the current fiscal year operating income increased 25% over the prior fiscal year, compared to the 70% decrease in net income for the same period. All of our investments are recorded at estimated fair value, and the valuation can be highly volatile.

CEO Comments

"We are very pleased with our performance including increasing sales and an increase of $1.4 million in operating income," said the Company's President and Chief Executive Officer Richard L. ("Rick") Van Kirk. "While this fiscal year included the challenges of transitioning to a multiple-facility operation, we continued to grow the business. I remain grateful to the entire Pro-Dex team for their ongoing efforts and teamwork."

Mr. Van Kirk continued, "Additionally, we are excited to announce that we hired a new Director of Operations in the first quarter of fiscal 2025, Mr. Jawahar Garg, who has extensive manufacturing operations and supply chain experience to assist our team to continue on our growth trajectory."

About Pro-Dex, Inc.

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex also sells rotary air motors. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.

Statements herein concerning the Company's plans, growth and strategies may include "forward-looking statements" within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance (including, but not limited to, prospects for future growth) as well as management's expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business risks of the Company set forth in the Company's filings with the Securities and Exchange Commission.

(tables follow)

PRO-DEX, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)

 

 

June 30,

 

 

 

2024

 

 

2023

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

2,631

 

 

$

2,936

 

Investments

 

 

4,217

 

 

 

1,134

 

Accounts receivable

 

 

13,887

 

 

 

9,952

 

Deferred costs

 

 

262

 

 

 

494

 

Inventory

 

 

15,269

 

 

 

16,167

 

Prepaid expenses

 

 

345

 

 

 

296

 

Total current assets

 

 

36,611

 

 

 

30,979

 

Land and building, net

 

 

6,155

 

 

 

6,249

 

Equipment and improvements, net

 

 

5,024

 

 

 

5,079

 

Right of use asset, net

 

 

1,473

 

 

 

1,872

 

Intangibles, net

 

 

54

 

 

 

81

 

Deferred income taxes, net

 

 

1,555

 

 

 

-

 

Investments

 

 

1,563

 

 

 

7,521

 

Other assets

 

 

42

 

 

 

42

 

Total assets

 

$

52,477

 

 

$

51,823

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

4,513

 

 

$

2,261

 

Accrued liabilities

 

 

3,359

 

 

 

3,135

 

Income taxes payable

 

 

632

 

 

 

453

 

Deferred revenue

 

 

14

 

 

 

-

 

Notes payable

 

 

4,374

 

 

 

3,827

 

Total current liabilities

 

 

12,892

 

 

 

9,676

 

Non-current liabilities:

 

 

 

 

 

 

 

 

Lease liability, net of current portion

 

 

1,182

 

 

 

1,638

 

Deferred income taxes, net

 

 

-

 

 

 

8

 

Notes payable, net of current portion

 

 

7,536

 

 

 

8,911

 

Total non-current liabilities

 

 

8,718

 

 

 

10,557

 

Total liabilities

 

 

21,610

 

 

 

20,233

 

 

 

 

 

 

 

 

 

 

Commitments and Contingencies:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shareholders' equity:

 

 

 

 

 

 

 

 

Common stock, no par value, 50,000,000 shares authorized; 3,363,412 and 3,545,309 shares issued and outstanding at June 30, 2024 and 2023, respectively

 

 

3,917

 

 

 

6,767

 

Retained earnings

 

 

26,950

 

 

 

24,823

 

Total shareholders' equity

 

 

30,867

 

 

 

31,590

 

Total liabilities and shareholders' equity

 

$

52,477

 

 

$

51,823

 

PRO-DEX, INC. AND SUBSIDIARY
CONSOLIDATED INCOME STATEMENTS
(In thousands, except per share data)

 

 

Three Months Ended
June 30,
(Unaudited)

 

 

Years Ended
June 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Net sales

 

$

15,025

 

 

$

10,639

 

 

$

53,844

 

 

$

46,087

 

Cost of sales

 

 

10,936

 

 

 

7,279

 

 

 

39,293

 

 

 

33,338

 

Gross profit

 

 

4,089

 

 

 

3,360

 

 

 

14,551

 

 

 

12,749

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling expenses

 

 

37

 

 

 

9

 

 

 

117

 

 

 

155

 

General and administrative expenses

 

 

864

 

 

 

1,046

 

 

 

4,072

 

 

 

4,028

 

Research and development costs

 

 

836

 

 

 

695

 

 

 

3,189

 

 

 

2,804

 

Total operating expenses

 

 

1,737

 

 

 

1,750

 

 

 

7,378

 

 

 

6,987

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income

 

 

2,352

 

 

 

1,610

 

 

 

7,173

 

 

 

5,762

 

Interest expense

 

 

(150

)

 

 

(145

)

 

 

(558

)

 

 

(533

)

Unrealized gain (loss) on investments

 

 

(340

)

 

 

492

 

 

 

(4,125

)

 

 

3,899

 

Gain on sale of investments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

6

 

Interest and dividend income

 

 

68

 

 

 

58

 

 

 

144

 

 

 

294

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income before income taxes

 

 

1,930

 

 

 

2,015

 

 

 

2,634

 

 

 

9,428

 

Income tax expense

 

 

343

 

 

 

514

 

 

 

507

 

 

 

2,354

 

Net income

 

$

1,587

 

 

$

1,501

 

 

$

2,127

 

 

$

7,074

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic & Diluted income per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net income per share

 

$

0.47

 

 

$

0.42

 

 

$

0.61

 

 

$

1.98

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted net income per share

 

$

0.46

 

 

$

0.42

 

 

$

0.60

 

 

$

1.95

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

3,400,767

 

 

 

3,545,309

 

 

 

3,498,807

 

 

 

3,571,044

 

Diluted

 

 

3,473,167

 

 

 

3,610,109

 

 

 

3,571,207

 

 

 

3,636,944

 

PRO-DEX, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

 

 

Years Ended June 30,

 

 

 

2024

 

 

2023

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net income

 

$

2,127

 

 

$

7,074

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

1,160

 

 

 

857

 

Unrealized (gain) loss on marketable equity investments

 

 

4,125

 

 

 

(3,899

)

Gain on sale of investments

 

 

-

 

 

 

(6

)

Non-cash lease recovery

 

 

(17

)

 

 

(2

)

Amortization of loan fees, net

 

 

(13

)

 

 

12

 

Share-based compensation

 

 

605

 

 

 

766

 

Deferred income taxes

 

 

(1,563

)

 

 

264

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(3,935

)

 

 

5,432

 

Deferred costs

 

 

232

 

 

 

216

 

Inventory

 

 

898

 

 

 

(3,489

)

Prepaid expenses

 

 

(49

)

 

 

494

 

Accounts payable and accrued expenses

 

 

2,436

 

 

 

(1,153

)

Deferred revenue

 

 

14

 

 

 

(1,013

)

Income taxes payable

 

 

179

 

 

 

(91

)

Net cash provided by operating activities

 

 

6,199

 

 

 

5,462

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Purchases of equipment and improvements

 

 

(983

)

 

 

(974

)

Proceeds from sale of investments

 

 

-

 

 

 

89

 

Investment in Monogram

 

 

(1,250

)

 

 

-

 

Net cash used in investing activities

 

 

(2,233

)

 

 

(885

)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Principal payments on notes payable

 

 

(4,816

)

 

 

(6,093

)

Borrowing from Minnesota Bank & Trust, net of loan origination fees

 

 

4,000

 

 

 

5,284

 

Repurchases of common stock

 

 

(3,505

)

 

 

(1,547

)

Payments of employee taxes on net issuance of common stock

 

 

-

 

 

 

(223

)

Proceeds from exercise of stock options and ESPP contributions

 

 

50

 

 

 

89

 

Net cash used in financing activities

 

 

(4,271

)

 

 

(2,490

)

 

 

 

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

 

(305

)

 

 

2,087

 

Cash and cash equivalents, beginning of year

 

 

2,936

 

 

 

849

 

Cash and cash equivalents, end of year

 

$

2,631

 

 

$

2,936

 

Contact: Richard L. Van Kirk, Chief Executive Officer
(949) 769-3200

Chimerix

Stock Quote

Last Trade: US$48.74
Daily Change: 2.39 5.16
Daily Volume: 64,599
Market Cap: US$158.890M

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB